Outlook Therapeutics, Inc.
OTLK · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $8,083 | $0 | $0 | $0 |
| + Debt | $248 | $0 | $0 | $0 |
| Enterprise Value | -$7,835 | $0 | $0 | $0 |
| Revenue | $1,414 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $57 | -$0 | -$0 | -$0 |
| % Margin | 4% | – | – | – |
| EBITDA | -$67,062 | -$0 | -$0 | -$0 |
| % Margin | -4,744.3% | – | – | – |
| Net Income | -$62,425 | -$0 | -$0 | -$0 |
| % Margin | -4,416.2% | – | – | – |
| EPS Diluted | -1.79 | -4.06 | -4.72 | -6.23 |
| % Growth | 55.9% | 14% | 24.2% | – |
| Operating Cash Flow | -$51,829 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$51,829 | -$0 | -$0 | -$0 |